title: Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
abstract: The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.
authors.affiliation: Third Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: A P
authors.initials: AP
authors.lastname: Chahinian
authors.forename: M
authors.initials: M
authors.lastname: Shinjo
authors.forename: A
authors.initials: A
authors.lastname: Tonomura
authors.forename: M
authors.initials: M
authors.lastname: Miyake
authors.forename: N
authors.initials: N
authors.lastname: Togawa
authors.forename: K
authors.initials: K
authors.lastname: Ninomiya
authors.forename: K
authors.initials: K
authors.lastname: Higashino
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood*; D002097:C-Reactive Protein / Q000032:analysis; D003937:Diagnosis, Differential; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D015850:Interleukin-6 / Q000032:analysis / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood / Q000473:pathology; D008654:Mesothelioma / Q000097:blood* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D009961:Orosomucoid / Q000032:analysis; D010996:Pleural Effusion / Q000097:blood / Q000737:chemistry; D010997:Pleural Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D010998:Pleurisy / Q000097:blood / Q000150:complications; D016019:Survival Analysis; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000150:complications; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D015850:Interleukin-6; D009961:Orosomucoid; D014409:Tumor Necrosis Factor-alpha; D005340:Fibrinogen; D002097:C-Reactive Protein